Spots Global Cancer Trial Database for locally advanced nsclc
Every month we try and update this database with for locally advanced nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | NCT05548504 | Non-small Cell ... Radiotherapy Si... Frailty | Photon Proton | 18 Years - | Odense University Hospital | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. | NCT04606303 | Locally Advance... | Toripalimab com... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | NCT05548504 | Non-small Cell ... Radiotherapy Si... Frailty | Photon Proton | 18 Years - | Odense University Hospital | |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | NCT05548504 | Non-small Cell ... Radiotherapy Si... Frailty | Photon Proton | 18 Years - | Odense University Hospital | |
| Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC | NCT03822351 | Stage III Non-s... Unresectable | Durvalumab + Ol... Durvalumab Durvalumab + Mo... | 18 Years - 99 Years | MedImmune LLC | |
| A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. | NCT04606303 | Locally Advance... | Toripalimab com... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | NCT05548504 | Non-small Cell ... Radiotherapy Si... Frailty | Photon Proton | 18 Years - | Odense University Hospital | |
| Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) | NCT01391260 | Non-small Cell ... | Gefitinib | 18 Years - 75 Years | ZhuGuangYing | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00497315 | Non-Small Cell ... | combination che... thoracic irradi... | 18 Years - | University Hospital, Antwerp |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
